The addition of GnRH antagonists in intrauterine insemination cycles with mild ovarian hyperstimulation does not increase live birth rates--a randomized, double-blinded, placebo-controlled trial.

What Was Tested

This randomized controlled trial looks at Follicle Stimulating Hormone.

Who Took Part

The age groups tagged for this paper are adults, women only.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and multicenter study.

Because people in this Follicle Stimulating Hormone study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Follicle Stimulating Hormone.

The comparison arm used a placebo, so changes seen with Follicle Stimulating Hormone could be set against what happens without it.

More than one site took part, so the participants came from several places.

A GnRH antagonist was added when one or more follicles of 14 mm diameter or more were visualized.

When at least one follicle reached a size of ≥18 mm, ovulation was induced by hCG injection.

A single IUI was performed 38-40 h later.

Couples were offered a maximum of three consecutive cycles.

The primary outcome of the trial was live births.

What Was Measured

Secondary outcomes were pregnancy rates, multiple pregnancy rates, miscarriages and ovarian hyperstimulation syndrome rate.

PubMed files the paper under topics including Birth Rate, Follicle Stimulating Hormone, Gonadotropin-Releasing Hormone, Insemination, Artificial, Ovarian Hyperstimulation Syndrome, Ovulation Induction and Pregnancy Rate.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Follicle Stimulating Hormone.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2011 (Human reproduction (Oxford, England)), a journal based in England.

More context: all human trials.